Cipla, India’s third-largest drugmaker by revenue, reported weaker-than-expected fourth-quarter earnings on Wednesday as weak sales and intense competition in its key US market weighed on performance.The company’s consolidated net profit fell 54.6% year-on-year to 5.55 billion rupees ($58 million) for the quarter ended March 31.The earnings figure came in below…
Japanese investors became net sellers of foreign stocks in April for the first time in four months, as concerns…
Walmart is cutting or relocating around 1,000 corporate employees as the retail giant consolidates parts of its global technology…
Hindustan Petroleum Corporation Limited reported a sharp rise in profit for the fourth quarter and full financial year 2025-26,…
European Central Bank board member Frank Elderson on Wednesday urged banks in the euro area to accelerate preparations against…
BT Group share price continued its strong bull run, reaching its highest point in over seven years as its…
Shares of India’s state-run Oil and Natural Gas Corporation (ONGC) surged by as much as 6% to hit an…
Rocket Lab stock (NASDAQ: RKLB) has become one of the market’s loudest momentum stories, and Cathie Wood has been…
The prolonged conflict in the Middle East is beginning to weigh heavily on global markets, affecting currencies, fuel prices,…